Intercept Pharma (ICPT) Tops Q1 EPS by 20c

Intercept Pharma (NASDAQ: ICPT) reported Q1 EPS of ($3.22), $0.20 better than the analyst estimate of ($3.42). Revenue for the quarter came in at $36 million versus the consensus estimate of $38.04 million.

2018 Financial Guidance

Based on our first quarter results and our current outlook for the remainder of 2018, we are announcing a 2018 Ocaliva net sales guidance range of between $170 million and $185 million. In addition, we are confirming our previously announced 2018 non-GAAP adjusted operating expenses guidance range of between $390 million and $410 million. See “Non-GAAP Financial Measures” below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Reading (RDI) Tops Q2 EPS by 4c